Day: May 30, 2026

Transitioning to efanesoctocog alfa was safe and effective in this paediatric cohort. Despite limited follow-up, data suggest this therapy offers meaningful clinical and psychosocial benefits.

To describe the experience of transitioning paediatric patients with HA to efanesoctocog alfa using a comprehensive assessment. Prospective observational study in a paediatric haemophilia unit. Patients